Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing

Journal of Clinical Oncology

Volumn 19, Issue 11, 2001, Pages 2875-2882

  Gabrilove, J L ^a   Cleeland, C S ^a   Livingston, R B ^a   Sarokhan, B ^a   Winer, E ^a   Einhorn, L H ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CORRELATION FUNCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; UNITED STATES;

EID: 0035366382     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.11.2875     Document Type: Article

References (19)

1. Impact of epoetin alfa in chemotherapy-associated anemia
2. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue
3. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
4. Erythropoietin for anaemia in cancer patients
5. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin
6. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy
7. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients
8. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
9. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
10. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
11. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated postsurgical setting: The importance of iron availability in optimizing response
12. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects
13. Toxicity and response criteria of the Eastern Cooperative Oncology Group
14. Assessment of the quality of life of patients with advanced cancer
15. Clinical applications of visual analog scales: A critical review
16. Interpretation of quality of life changes
17. Response to recombinant human erythropoietin (rHuEpo) in patients with cancer-related anaemia
18. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO)
19. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery